Strategy for the management of vasovagal syncope

Drugs and Aging

Volumn 19, Issue 3, 2002, Pages 179-202

  Bloomfield, Daniel M ^a  

^a Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; FLUDROCORTISONE; MIDODRINE; RECOMBINANT ERYTHROPOIETIN; SEROTONIN UPTAKE INHIBITOR; THEOPHYLLINE; VERAPAMIL;

ALGORITHM; ARTIFICIAL HEART PACEMAKER; AUTONOMIC NERVOUS SYSTEM; CLINICAL TRIAL; DEHYDRATION; DRUG EFFICACY; FLUID INTAKE; HUMAN; HYPOTENSION; INJURY; OCCUPATIONAL HAZARD; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PATIENT EDUCATION; PRIORITY JOURNAL; PROVOCATION TEST; RECURRENT DISEASE; REVIEW; SALT INTAKE; SYNCOPE; TILT TABLE TEST;

EID: 0036282941     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219030-00003     Document Type: Review

References (98)

1. Head-up tilt: A useful test for investigating unexplained syncope
2. Midodrine: A role in the management of neurocardiogenic syncope
3. Effect of etilefrine in preventing syncopal recurrence in patients with vasovagal syncope: A double-blind, randomized, placebo-controlled trial. The Vasovagal Syncope International study
4. Randomized double-blind, placebo-controlled trial of oral atenolol in patients with unexplained syncope and positive upright tilt table test results
5. The North American Vasovagal Pacemaker Study (VPS). A randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope
6. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: A randomized, double-blind, placebo-controlled study
7. Randomized, double-blind, placebo-controlled trial of oral enalapril in patients with neurally mediated syncope
8. Putting it together: A new treatment algorithm for vasovagal syncope and related disorders
9. Clinical disorders of the autonomic nervous system associated with orthostatic intolerance: An overview of classification, clinical evaluation, and management
10. The elusive pathophysiology of neurally mediated syncope
11. Increased activity in left ventricular receptors during hemorrhage or occlusion of caval veins in the cat - A possible cause of the vaso-vagal reaction
12. Pharmacologic approaches to therapy for vasovagal syncope
13. The clinical spectrum of neurocardiogenic syncope
14. Vasovagal reactions may occur after orthotopic heart transplantation
15. Vasodepressor syncope in a cardiac transplant recipient: A case of vagal re-innervation
16. Yohimbine in neurally mediated syncope. Pathophysiological implications
17. Pathophysiology and differential diagnosis of neurocardiogenic syncope
18. Neurally mediated syncopal syndromes: Pathophysiological concepts and clinical evaluation
19. The economics of treating vasovagal syncope
20. Effects of age on outcome of tilt-table testing
21. Methodology of head-up tilt testing in patients with unexplained syncope
22. Delayed orthostatic intolerance
23. Neurocardiogenic syncope
24. The postural orthostatic tachycardia syndrome: A neurocardiogenic variant identified during head-up tilt table testing
25. Chronic orthostatic intolerance: Part of a spectrum of dysfunction in orthostatic cardiovascular homeostasis?
26. Hyperdynamic beta-adrenergic circulatory state. Increased beta-receptor responsiveness
27. Idiopathic hypovolemia
28. Abnormal orthostatic changes in blood pressure and heart rate in subjects with intact sympathetic nervous function: Evidence for excessive venous pooling
29. Comparison of the postural tachycardia syndrome (POTS) with orthostatic hypotension due to autonomic failure
30. Idiopathic postural orthostatic tachycardia syndrome: An attenuated form of acute pandysautonomia?
31. Proposed classification for tilt induced vasovagal syncope
32. Indications, methodology, and classification of results of tilt-table testing
33. Tilt table testing for assessing syncope
34. Tilting towards a diagnosis in recurrent unexplained syncope
35. Provocation of bradycardia and hypotension by isoproterenol and upright posture in patients with unexplained syncope
36. Tilt table testing for evaluation of neurally-mediated (cardioneurogenic) syncope: Rationale and proposed protocols
37. Value of head-up tilt testing potentiated with sublingual nitroglycerin to assess the origin of unexplained syncope
38. Impairment of physical and psychosocial function in recurrent syncope
39. Health-related quality of life in patients with neuromediated syncope
40. Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally mediated syncope
41. Syncope recurrence can better be predicted by history than by head-up tilt testing in untreated patients with suspected neurally mediated syncope
42. Recurrence of neurocardiogenic syncope without pharmacologic interventions
43. Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope
44. Timing of first recurrence of syncope predicts syncopal frequency after a positive tilt table test result
45. The clinical and prognostic significance of the asystolic response during the head-up tilt test
46. Drug-related syncope
47. The relationship between neurally-mediated hypotension and the chronic fatigue syndrome
48. Salt supplement increases plasma volume and orthostatic tolerance in patients with unexplained syncope
49. Oral fluid therapy. A promising treatment for vasodepressor syncope
50. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope
51. A placebo-controlled trial of intravenous and oral disopyramide for prevention of neurally-mediated syncope induced by head-up tilt
52. Usefulness of transdermal scopolamine for vasovagal syncope
53. Malignant vasovagal syncope: A randomised trial of metoprolol and clonidine
54. Acute and long-term beta-adrenergic blockade for patients with neurocardiogenic syncope
55. Changes in plasma epinephrine concentration and in heart rate during head-up tilt testing in patients with neurocardiogenic syncope: Correlation with successful therapy with beta-receptor antagonists
56. Use of intravenous esmolol to predict efficacy of oral beta-adrenergic blocker therapy in patients with neurocardiogenic syncope
57. Efficacy of different treatment strategies for neurocardiogenic syncope
58. Effect of beta blockers on the time to first syncope recurrence in patients after a positive isoproterenol tilt table test
59. Response to beta blockers in patients with neurocardiogenic syncope: How to predict beneficial effects
60. Absence of tachycardia during tilt test predicts failure of beta-blocker therapy in patients with neurocardiogenic syncope
61. Multiple system atrophy and pure autonomic failure
62. Effects of fludrocortisone on sympathetic nerve activity in humans
63. The use of head-upright tilt table testing in the evaluation and management of syncope in children and adolescents
64. Fludrocortisone in the treatment of hypotensive disorders in the elderly
65. Efficacy of alpha-adrenergic agonist therapy for prevention of pediatric neurocardiogenic syncope
66. Efficacy of midodrine hydrochloride in neurocardiogenic syncope refractory to standard therapy
67. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
68. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: A randomized, double-blind multicenter study
69. The use of methylphenidate in the treatment of refractory neurocardiogenic syncope
70. Beneficial effects of dextro-amphetamine in the treatment of vasodepressor syncope
71. Usefulness of fluoxetine hydrochloride for prevention of resistant upright tilt induced syncope
72. Use of sertraline hydrochloride in the treatment of refractory neurocardiogenic syncope in children and adolescents
73. The role of serotonin re-uptake inhibitors in preventing recurrent unexplained childhood syncope - A preliminary report
74. Exacerbations of neurally mediated syncope associated with sertraline
75. Fluoxetine hydrochloride for the treatment of severe refractory orthostatic hypotension
76. Relation between myocardial beta-adrenoceptor density and hemodynamic and neurohumoral changes in a rat model of chronic myocardial infarction: Effects of ibopamine and captopril
77. Modulation of noradrenaline release in the pithed rabbit: A role for angiotensin II
78. Comparison of cardiac pacing with drug therapy in the treatment of neurocardiogenic (vaso-vagal) syncope with bradycardia or asystole
79. Usefulness of disopyramide for prevention of upright tilt-induced hypotension-bradycardia
80. Effects of transdermal scopolamine on heart rate variability in normal subjects
81. Utility of upright tilt-table testing in the evaluation and management of syncope of unknown origin
82. Clinical efficacy of propantheline bromide in neurocardiogenic syncope: Pharmacodynamic implications
83. The autonomic and hemodynamic effects of oral theophylline in patients with vasodepressor syncope
84. Excessive myocardial contraction in vasovagal syncope demonstrated by echocardiography during head-up tilt test
85. Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group
86. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation)
87. Role of pacing in the treatment of vasovagal syncope
88. Permanent pacing for cardioinhibitory malignant vasovagal syndrome
89. DDD pacing with rate drop response function versus DDI with rate hysteresis pacing for cardioinhibitory vasovagal syncope
90. Dual chamber pacing aborts vasovagal syncope induced by head-up 60 degrees tilt
91. Comparison of single and dual chamber pacing techniques in prevention of upright tilt induced vasovagal syncope
92. Cardiac pacing does not improve orthostatic tolerance in patients with vasovagal syncope
93. Clinical experience with Thera DR rate-drop response pacing algorithm in carotid sinus syndrome and vasovagal syncope
94. Tilt training: A new treatment for recurrent neurocardiogenic syncope and severe orthostatic intolerance
95. Tilt training: A treatment for malignant and recurrent neurocardiogenic syncope
96. Usefulness of a tilt training program for the prevention of refractory neurocardiogenic syncope in adolescents: A controlled study
97. A controlled trial of acute and long term medical therapy in tilt-induced neurally mediated syncope
98. Limitations of head-up tilt test for evaluating the efficacy of therapeutic interventions in patients with vasovagal syncope: Results of a controlled study of etilefrine versus placebo